222 related articles for article (PubMed ID: 16142997)
21. Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load.
Neben K; Jauch A; Hielscher T; Hillengass J; Lehners N; Seckinger A; Granzow M; Raab MS; Ho AD; Goldschmidt H; Hose D
J Clin Oncol; 2013 Dec; 31(34):4325-32. PubMed ID: 24145347
[TBL] [Abstract][Full Text] [Related]
22. Risk stratification of patients with newly diagnosed multiple myeloma: optimizing treatment based on pretreatment characteristics.
Chng WJ; Fonseca R
Clin Lymphoma Myeloma; 2005 Nov; 6(3):200-7. PubMed ID: 16354325
[TBL] [Abstract][Full Text] [Related]
23. Clonal Evolution in Multiple Myeloma.
Fakhri B; Vij R
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S130-4. PubMed ID: 27521309
[TBL] [Abstract][Full Text] [Related]
24. The impact of intra-clonal heterogeneity on the treatment of multiple myeloma.
Brioli A; Melchor L; Cavo M; Morgan GJ
Br J Haematol; 2014 May; 165(4):441-54. PubMed ID: 24580032
[TBL] [Abstract][Full Text] [Related]
25. Molecular profiling of multiple myeloma: from gene expression analysis to next-generation sequencing.
Agnelli L; Tassone P; Neri A
Expert Opin Biol Ther; 2013 Jun; 13 Suppl 1():S55-68. PubMed ID: 23614397
[TBL] [Abstract][Full Text] [Related]
26. Genomics in multiple myeloma research.
Sevcíková S; Nemec P; Pour L; Hájek R
Klin Onkol; 2011; 24 Suppl():S34-8. PubMed ID: 21923062
[TBL] [Abstract][Full Text] [Related]
27. Gene expression profiling and multiple myeloma.
Shaughnessy J; Zhan F; Barlogie B; Stewart AK
Best Pract Res Clin Haematol; 2005; 18(4):537-52. PubMed ID: 16026736
[TBL] [Abstract][Full Text] [Related]
28. Genomics and proteomics in multiple myeloma and Waldenström macroglobulinemia.
Henry T; Fonseca R
Curr Opin Hematol; 2007 Jul; 14(4):369-74. PubMed ID: 17534163
[TBL] [Abstract][Full Text] [Related]
29. Genetic Abnormalities in Multiple Myeloma: Prognostic and Therapeutic Implications.
Cardona-Benavides IJ; de Ramón C; Gutiérrez NC
Cells; 2021 Feb; 10(2):. PubMed ID: 33562668
[TBL] [Abstract][Full Text] [Related]
30. Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling.
Chng WJ; Kumar S; Vanwier S; Ahmann G; Price-Troska T; Henderson K; Chung TH; Kim S; Mulligan G; Bryant B; Carpten J; Gertz M; Rajkumar SV; Lacy M; Dispenzieri A; Kyle R; Greipp P; Bergsagel PL; Fonseca R
Cancer Res; 2007 Apr; 67(7):2982-9. PubMed ID: 17409404
[TBL] [Abstract][Full Text] [Related]
31. A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy.
Stewart AK; Bergsagel PL; Greipp PR; Dispenzieri A; Gertz MA; Hayman SR; Kumar S; Lacy MQ; Lust JA; Russell SJ; Witzig TE; Zeldenrust SR; Dingli D; Reeder CB; Roy V; Kyle RA; Rajkumar SV; Fonseca R
Leukemia; 2007 Mar; 21(3):529-34. PubMed ID: 17230230
[TBL] [Abstract][Full Text] [Related]
32. Non-coding RNA: a novel opportunity for the personalized treatment of multiple myeloma.
Amodio N; Di Martino MT; Neri A; Tagliaferri P; Tassone P
Expert Opin Biol Ther; 2013 Jun; 13 Suppl 1():S125-37. PubMed ID: 23692413
[TBL] [Abstract][Full Text] [Related]
33. Genomic profiling of multiple myeloma: New insights and modern technologies.
Hultcrantz M; Yellapantula V; Rustad EH
Best Pract Res Clin Haematol; 2020 Mar; 33(1):101153. PubMed ID: 32139018
[TBL] [Abstract][Full Text] [Related]
34. Risk stratification in the era of novel therapies.
San-Miguel J; Mateos MV; Gutierrez NC
Cancer J; 2009; 15(6):457-64. PubMed ID: 20010164
[TBL] [Abstract][Full Text] [Related]
35. Ultra high-risk myeloma.
Avet-Loiseau H
Hematology Am Soc Hematol Educ Program; 2010; 2010():489-93. PubMed ID: 21239841
[TBL] [Abstract][Full Text] [Related]
36. Cyclin kinase subunit 1B nuclear expression predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with bortezomib.
Chen MH; Qi C; Reece D; Chang H
Hum Pathol; 2012 Jun; 43(6):858-64. PubMed ID: 22047644
[TBL] [Abstract][Full Text] [Related]
37. Evaluating gene expression profiling by quantitative polymerase chain reaction to develop a clinically feasible test for outcome prediction in multiple myeloma.
Sarasquete ME; Martínez-López J; Chillón MC; Alcoceba M; Corchete LA; Paiva B; Puig N; Sebastián E; Jiménez C; Mateos MV; Oriol A; Rosiñol L; Palomera L; Teruel AI; González Y; Lahuerta JJ; Bladé J; Gutiérrez NC; Fernández-Redondo E; González M; San Miguel JF; García-Sanz R
Br J Haematol; 2013 Oct; 163(2):223-34. PubMed ID: 23952215
[TBL] [Abstract][Full Text] [Related]
38. An abnormal nonhyperdiploid karyotype is a significant adverse prognostic factor for multiple myeloma in the bortezomib era.
Tan D; Teoh G; Lau LC; Lim A; Lim TH; Yap KC; Premalatha P; Lao ZT; Wee N; Choo C; Wee HC; Su S; Lee YS; Lee LH; Hwang W; Goh YT
Am J Hematol; 2010 Oct; 85(10):752-6. PubMed ID: 20721886
[TBL] [Abstract][Full Text] [Related]
39. Synopsis of a roundtable on validating novel therapeutics for multiple myeloma.
Dalton W; Anderson KC
Clin Cancer Res; 2006 Nov; 12(22):6603-10. PubMed ID: 17121878
[TBL] [Abstract][Full Text] [Related]
40. Comparative genomic hybridisation identifies two variants of smoldering multiple myeloma.
Rosiñol L; Carrió A; Bladé J; Queralt R; Aymerich M; Cibeira MT; Esteve J; Rozman M; Campo E; Montserrat E
Br J Haematol; 2005 Sep; 130(5):729-32. PubMed ID: 16115129
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
